Perimeter Medical Imaging Ai Inc · TSXV:PINK
Perimeter Medical Imaging Ai — Q4 2025 Earnings Presentation
34 slides from Perimeter Medical Imaging Ai's earnings presentation, Mar 31, 2026
Slide 1: Transforming Cancer Surgery with Advanced Visualization and AI
Transforming Cancer Surgery with Advanced Visualization and AI MARCH 2026 TSXV: PINK | OTCQX: PYNKF INVESTOR PRESENTATION © 2026 Perimeter Medical Imaging AI, Inc. 1
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking forward statements. Words such as “may,” “would,” “could,” “will,” “likely,” “believe,” “expect,” “anticipate,” “intend,” “plan,” “estimate,” and similar words and the negative form thereof are used to identify forward-looking sta
Slide 3: Indications for Use Disclosures
Indications for Use Disclosures S-Series OCT Claire OCT The S-Series OCT is indicated for use as an imaging tool in the evaluation of The Perimeter Claire OCT System is an adjunctive three-dimensional excised human tissue microstructure, by providing two-dimensional, cross- imaging tool which provid
Slide 4: We Didn't Get It All
We didn’t get it all. A conversation no surgeon wants to have with their patients… 4
Slide 5: Perimeter Overview, Patented OCT Solution, Market Opportunity, Growth Strategy
1 Perimeter Overview 2 Perimeter’s Patented OCT Solution 3 Market Opportunity 4 Growth Strategy & Financial Model 5
Slide 6: Investment Highlights
Investment Highlights First FDA-Approved AI Imaging Device for Breast Cancer Surgery Claire received FDA PMA approval in March 2026, establishing a first-of-its- kind AI-enabled surgical imaging platform Clinical Trial Showed Improved Surgical Outcomes Pivotal trial demonstrated adjunctive use resul
Slide 7: Perimeter Medical: Transforming Cancer Surgery
Perimeter Medical: Transforming Cancer Surgery About Perimeter Established Platform Perimeter Medical is advancing cancer surgery with optical imaging designed to help surgeons achieve clear margins during 3,500+ 22 Procedures Hospitals procedures • Patented imagining solution, S-Series OCT has 510(
Slide 8: Perimeter Overview, Patented OCT Solution, Market Opportunity, Growth Strategy
1 Perimeter Overview 2 Perimeter’s Patented OCT Solution 3 Market Opportunity 4 Growth Strategy & Financial Model 8
Slide 9: It's All About Getting Clean Margins, the First Time
The Goal It’s All About Getting Clean Margins, the First Time Negative or Clean Margin Positive Margins Repeat Surgery Even for skilled surgeons, the odds of needing a repeat (re-excision) surgery due to positive margins are relatively high - nearly 1 in 4 for some types of cancer Positive Margin 23
Slide 10: Our Solution: Benefits of Optical Coherence Tomography
Our Solution Benefits of Optical Coherence Tomography (OCT) Ultra-high-resolution imaging of tissue microstructures 10x sharper than ultrasound & X-Ray 100x more detailed than MRI OCT Proven in clinical fields: Retina, heart, skin ULTRASOUND MRI Cellular-level Subsurface imaging No injectables & vis
Slide 11: OCT Imaging + AI Sees Beneath the Tissue Surface
OCT Imaging + AI Sees Beneath the Tissue Surface Claire combines Perimeter’s patented OCT imaging with AI guidance to highlight tissue regions suspicious for cancer, helping surgeons focus on achieving clear margins during surgery Claire’s AI was trained on Perimeter’s proprietary OCT image library
Slide 12: Introducing Claire
FDA Approved, AI-Enabled, Real-Time, 3D Imaging Device Introducing Claire Claire’s FDA approval marks a major milestone in breast cancer surgery, advancing Perimeter’s mission to reduce repeat procedures so no patient has to hear: “We didn’t get it all.” Reduce Positive Confidence Residual Margins1
Slide 13: Claire FDA PMA Application Approved
Breakthrough-Device-Designated Claire FDA PMA Application Approved Establishes Claire as a First-of-Its-Kind AI Surgical Imaging Platform First AI-Enabled Trial Demonstrated FDA Approval Approved with Imaging Device for Super Superiority Through Rigorous Predetermined Change Breast Cancer Surgery Ma
Slide 14: Claire FDA Approval Generated Positive Media Coverage
Claire FDA Approval Generated Positive Media Coverage Broad Industry Coverage Across Oncology, Radiology, and Healthcare Media State Farm still believes in CityLine | Corgan AdvaMed® Digital Health Tech™ - Radiology Business AdvaMed® Radius Research Presents Tantalus ... D CEO Magazine | Dallas TX B
Slide 15: A Path to Better Patient Outcomes
Advancing the Current Standard of Care A Path to Better Patient Outcomes Current Standard of Care** Reoperations impact cosmesis, Lucy’s delay treatment, Patient and increase risks Journey Resection Up to 10 Days Waiting Period Post-Op Pathology/Action Perimeter Solution* OCT has potential to minimi
Slide 16: Perimeter Overview, Patented OCT Solution, Market Opportunity, Growth Strategy
1 Perimeter Overview 2 Perimeter’s Patented OCT Solution 3 Market Opportunity 4 Growth Strategy & Financial Model 16
Slide 17: Pursuing Large Opportunities
Total Available Market Pursuing Large Opportunities Perimeter’s OCT-AI platform is initially focused on breast cancer Global TAM surgery and has the potential to expand into additional surgical oncology, biopsy, and pathology applications ~$17B* Strategy U.S. Addressable Market Breast Cancer Initial
Slide 18: Testimonials, Surgeons & Patients Benefit
Testimonials, Surgeons & Patients Benefit Add Product / Solution Slide(s)? Sommer Gunia Nadia Beth DuPree Jennifer DO, FACOS Patient MD, FACS, ABOIM Patient As a breast surgeon dedicated to I'm grateful to have a technology In the OR, Perimeter’s technology “I wish that I’d known to ask my precision
Slide 19: Adding Value Across the Continuum of Care
OCT Has the Potential to Improve Surgical Outcomes While Reducing Costs Across the Healthcare Ecosystem Adding Value Across the Continuum of Care Patients Payers • Reduced emotional and physical burden • Re-excisions represent ~$600M annual cost in • Faster treatment timeline breast cancer surgeries
Slide 20: Clear Surgical Margins Are Critical for Patient Outcomes
Perimeter Focused on Reducing Repeat Surgeries by Enabling Clearer Surgical Margins Clear Surgical Margins Are Critical for Patient Outcomes Clear Margins Improve Outcomes Negative surgical margins are associated with Approximate 5-Year Survival Rates higher survival rates 100% Consistent Across Tum
Slide 21: Perimeter OCT Continues to Evolve
Perimeter OCT Continues to Evolve OCT + AI 2021-2026 FDA APPROVED MARCH 2026 IN DEVELOPMENT Perimeter Claire with AI 2.02 Claire with AI 3.04 S-Series OCT1 Real-time visualization with State-of-the-art AI + More data Real-time visualization ImgAssist 2.0 Improved accuracy with ImgAssist 3.0 • 400-90
Slide 22: Perimeter Overview, Patented OCT Solution, Market Opportunity, Growth Strategy
1 Perimeter Overview 2 Perimeter’s Patented OCT Solution 3 Market Opportunity 4 Growth Strategy & Financial Model 22
Slide 23: Strategic Path to Scale and Profitability
Commercialization Evolution Strategic Path to Scale and Profitability Where We Were at the End of 2025 2026 – 2027 Operating Plan 2028+ • 22 systems deployed in commercial use • Launch Claire AI system • Expand beyond core breast surgery into adjacent indications • Operating strategy centered on FDA
Slide 24: Current Customers & Opportunity
Current Customers & Opportunity Significant Untouched & Low Hanging Market Potential Currently • 8 Regions CALI & PACIFIC NW MIDWEST & NEW ENGLAND • 22 placements • Imaged over 3,000 $80M $145M OPPORTUNITY patients to date OPPORTUNITY NYC & MID ATLANTIC Opportunity $95M Entirety of SAM* is $650M OPP
Slide 25: Three Pillars of Perimeter's Commercial Strategy
Three Pillars of Perimeter’s Commercial Strategy 1 Drive Utilization Promote consistent intraoperative use and procedural integration to drive sustained utilization 2 Pursue System Wide Sales Expand across hospital systems driven by demonstrated clinical value, workflow integration, and economic ali
Slide 26: High-Margin, Recurring Revenue Platform
High-Margin, Recurring Revenue Platform Hardware Consumable Service Software Specimen Immobilizer Service Contracts AI Upgrades Procedure-driven Ongoing service revenue AI software updates that consumable aids in supporting system uptime enhance guidance, positioning diverse tissue and clinical perf
Slide 27: Clear Path to Scaled Revenue
Clear Path to Scaled Revenue Illustrative Revenue Opportunity at Scale With ~6,000 U.S. hospitals performing 1M+ cancer surgeries annually, even modest adoption could drive meaningful revenue growth Initial Commercial Focus: Market Share 5% 10% 15% 20% 25% 50% Breast Cancer Surgery Est. Procedures 1
Slide 28: Attractive Financial Model
Path to Financial Stability Attractive Financial Model Multi-year growth Large, underpenetrated addressable market with multi-year adoption and expansion runway opportunity Recurring consumable High-margin, procedure-driven consumable usage creates durable recurring revenue revenue that scales with
Slide 29: Q1'25 & Beyond: Gaining Market Share
Impact of Capital Equipment & Consumables Q1’25 & Beyond: Gaining Market Share Revenue consists mainly of Service Fees, Consumables, & Capital Sales BEYOND $550K* $536K* $505K* $323K $439K Following FDA approval of Claire $293k $293k OCT, Company expects large pickup in Device Placements + $208k New
Slide 30: Opportunity is Well-Protected
Opportunity is Well-Protected • 6 issued patents, 6 pending and provisional patents both U.S. and internationally • Protected IP areas includes • Advanced image processing/ reconstruction algorithms • Tissue differentiation and imaging • Tissue management systems • Combining OCT and X-ray modalities
Slide 31: Strong Leadership
Unique Combination of AI & Medtech Experience Strong Leadership Adrian Mendes Andrew Berkeley Sara Brien Dr. Ted James Carl Gazdzinski Abbey Goodman Chief Executive Officer Co-Founder and Chief Financial Officer Chief Medical Officer VP, Engineering & VP, Sales Chief Innovation Officer Manufacturing
Slide 32: Capital Structure
Capital Structure Ticker Symbols TSXV: PINK | OTCQX: PYNKF Analyst Coverage COMMON SHARES 131,120,6161 FIRM ANALYST MARKET CAPITALIZATION ~C$45.0MM Leede Jones Gable Douglas W. Loe Social Capital Master Holdings, Paradigm Capital Scott McAuley LLC, 22.2% MAJOR SHAREHOLDERS Adrian Mendes, 11.6% Raymo
Slide 33: In Summary – Perimeter is Ready to Scale
In Summary – Perimeter is Ready to Scale Following Claire’s March 2026 FDA approval, Perimeter is positioned to scale and expand its AI-enabled surgical imaging platform First-of-Its-Kind AI Solving an Unmet ~$4 Billion Long- Surgical Imaging Surgical Need Term Opportunity FDA-approved AI imaging Re
Slide 34: Investor Relations Contact
Investor Relations Contact: skilmer@perimetermed.com TSXV: PINK | OTCQX: PYNKF @Perimeter Medical Imaging @perimetermed IR-122 rev H
Perimeter Medical Imaging AI — Q4 2025 Earnings Presentation on 6ix